Employees: 174
Size Anteris Technologies Global (AVR) is a United States Health Care company (Medical Specialties) with a market value of $508M, the 2661st largest of 3,085 United States companies the cockpit tracks. Shares closed at $5.21 on 18 Nov 2026.
Performance Over six months the shares fell 39.6%, against -16.1% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 9.0% over the last twelve months (peer median +6.3%); the operating margin is -4,880.4% (peer median 3.5%).
Valuation It trades at 2.24× book value against a peer median of 1.57× (6th most expensive of 20).
Price implies The share price implies a return on equity of about 30.2%; Anteris Technologies Global delivers -93.8%, so the price asks more than the business earns today.
Short interest Short interest is 9.3% of the free float (30 Oct 2026).
Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.33M | $1.91M | $2.70M | $2.73M | $3.20M |
| Revenue growth | — | -29% | -1% | -15% | — |
| Gross profit | -$49,000 | -$317,000 | -$241,000 | -$280,923 | -$475,694 |
| EBITDA | -$112M | -$92.2M | -$76.9M | -$46.2M | -$32.0M |
| Net income | -$108M | -$94.1M | -$76.3M | -$46.0M | -$30.6M |
| Free cash flow | -$93.5M | -$79.8M | -$63.5M | -$37.0M | -$31.0M |
| Capital expenditure | $2.62M | $1.95M | $2.28M | $2.39M | $1.67M |
| Total debt | $16.1M | $2.28M | $1.40M | $1.69M | $952,787 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AVR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.2% | -3.8% | 2nd lowest of 21 |
| 6-month return | -39.6% | -16.1% | 4th lowest of 21 |
| Return on equity | -93.8% | 1.8% | lowest of 20 |
| Price / book | 2.24× | 1.57× | 6th most expensive of 20 |
| ROE the price implies | 30.2% | 11.8% | 2nd most demanding of 20 |
| ROE delivered | -93.8% | 1.8% | lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| Anteris Technologies Global AVR | United States | $508M | -40% | +9% | -94% | 2.24× | 30.2% | -93.8% |
| Assure Tech (Hangzhou) 688075.SS | China | $508M | -27% | -9% | 0% | 0.67× | 6.4% | -0.5% |
| Shofu 7979.T | Japan | $510M | +32% | +9% | 13% | 1.57× | 7.6% | 12.9% |
| Guangdong Hybribio Biotech 300639.SZ | China | $511M | -18% | -7% | 2% | 0.85× | 5.0% | 1.8% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $500M | -27% | +18% | -11% | 0.56× | 5.3% | -10.9% |
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 9% | 1.94× | 21.7% | 9.5% |
| Anbio Biotechnology NNNN | United States | $518M | -89% | +10% | 27% | 4.46× | 79.1% | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $518M | -9% | +14% | 3% | 1.14× | 7.9% | 3.4% |
| medmix MEDX.SW | Switzerland | $494M | +11% | -7% | 0% | 0.97× | 6.4% | 0.0% |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 1% | 1.33× | 11.8% | 1.1% |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | n/a | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -40% | 1.97× | 23.1% | -40.2% |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 4% | 0.87× | 17.8% | 4.0% |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -1% | 0.55× | 3.1% | -1.2% |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 3% | 0.82× | 5.4% | 3.0% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 16% | 3.71× | 18.3% | 15.8% |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -10% | 2.91× | 18.4% | -10.2% |
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 15% | 5.20× | 21.5% | 15.5% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 4% | 2.07× | 18.2% | 4.1% |
| AngioDynamics ANGO | United States | $476M | -4% | +8% | -19% | 2.93× | 13.4% | -19.2% |
| WELL LEAD MEDICAL 603309.SS | China | $473M | -22% | +1% | 2% | 1.73× | 9.3% | 1.8% |